MENU
+Compare
MRNA
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$27.72
Change
+$0.56 (+2.06%)
Capitalization
10.72B

MRNA Moderna Forecast, Technical & Fundamental Analysis

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018... Show more

Industry: #Biotechnology
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for MRNA with price predictions
Apr 01, 2025

Aroon Indicator for MRNA shows an upward move is likely

MRNA's Aroon Indicator triggered a bullish signal on March 24, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator showed a similar pattern. In of the 180 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on March 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.983) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (3.328) is also within normal values, averaging (251.391).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MRNA is expected to report earnings to rise 6.19% to -308 cents per share on May 01

Moderna MRNA Stock Earnings Reports
Q1'25
Est.
$-3.09
Q4'24
Missed
by $0.18
Q3'24
Beat
by $1.95
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.48
The last earnings report on February 14 showed earnings per share of -291 cents, missing the estimate of -273 cents. With 11.68M shares outstanding, the current market capitalization sits at 10.72B.
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Technology Square
Phone
+1 617 714-6500
Employees
5600
Web
https://www.modernatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NTSX45.580.27
+0.60%
WisdomTree U.S. Efficient Core Fund
FAB79.760.25
+0.31%
First Trust Multi Cap Val AlphaDEX® ETF
VSHY21.65N/A
N/A
Virtus Newfleet Short Dur Hi Yld Bd ETF
IVE190.33-0.25
-0.13%
iShares S&P 500 Value ETF
EFT12.46-0.09
-0.72%
Eaton Vance Floating-Rate Income Trust

MRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
-4.20%
BNTX - MRNA
53%
Loosely correlated
-0.85%
RCKT - MRNA
50%
Loosely correlated
-12.89%
CVAC - MRNA
43%
Loosely correlated
-1.81%
CRSP - MRNA
40%
Loosely correlated
-2.62%
PRME - MRNA
39%
Loosely correlated
-10.30%
More